ALBERT

Description: Objectives Fever during neutropenia occurs in 〉 90% and 80% of allogeneic and autologous hematopoietic stem cell transplantation (HSCT) recipients, respectively. Current guidelines recommend the prophylaxis with fluoroquinolones (FQs) in HSCT patients. Although there is evidence that antibiotic prophylaxis improve clinical outcome in patients with chemotherapy-induced neutropenia, prophylactic antibiotic therapy has not been thoroughly evaluated in HSCT recipients. Therefore, we performed a meta-analysis to evaluate the impact of systemic antibiotic prophylaxis in HSCT recipients on mortality, incidence of infection and related adverse events. Data sources We identified reports that were not restricted to those in English and not restricted to published trials through PubMed, the Cochrane Library, and references of identified studies. Review Methods We included prospective, randomized studies on systemic antibiotic prophylaxis in HSCT recipients. The outcome measures included the all-cause mortality, infection-related mortality, febrile episodes, incidence of clinically or microbiologically documented infection, bacteremia, or related adverse events. The summarized odds ratios (ORs) were calculated using the Mantel–Haenszel method and the DerSimonian–Laird method. Results Seventeen trials with 1453 patients (842 autologous and 407 allogeneic HSCT recipients) were included. The percentage of autologous and allogeneic HSCT recipients was not specified in 2 trials. Systemic antibiotic prophylaxis was compared with placebo or no prophylaxis in 10 trials and with non-absorbable antibiotic in 2 trials, respectively. Systemic antibiotics other than FQs were evaluated in five out of these 12 trials. Four trials evaluated the effect of addition of antibiotics for gram positive bacteria to FQs. Remaining 1 trial compared the two different systemic antibiotic regimens, FQs versus trimethoprim sulfamethoxazole. As a result, systemic antibiotic prophylaxis reduced the incidence of febrile episodes (OR 0.16; 95 percent confidence interval [CI], 0.09-0.30), clinically or microbiologically documented infection (OR 0.41; 95% CI 0.30-0.57) and bacteremia (OR 0.37; 95% CI 0.26-0.53) without the significant effect on all-cause mortality or infection-related mortality (OR 0.89; 95% CI 0.48-1.66, OR 1.37; 95% CI 0.50-3.76, respectively). Impact of prophylaxis with FQs on mortality was inconclusive because of small number of clinical trials evaluated. Adverse events increased in patients with systemic antibiotic prophylaxis compared to controls (OR 3.32; 95% CI 1.45-7.63). In meta-regression, percentage of allogeneic HSCT recipients was not associated with each outcome measure. With regard to the comparison between different prophylactic regimens, addition of antibiotics for gram positive bacteria to FQs decreased the incidence of bacteremia (OR 0.44; 0.24-0.80) without significant effects on all-cause mortality, infection related death and febrile episodes. There was not significant, but consistent decrease in clinically or microbiologically documented infection (OR 0.55; 95% CI 0.30-1.01). There was significant increase of adverse events in patients receiving addition of antibiotics for gram positive bacteria to FQs (OR 6.65; 95% CI 2.15-20.54). Conclusions Systemic antibiotic prophylaxis successfully reduced the incidence of infection in HSCT recipients. However, there was no significant impact on mortality. Impact of prophylaxis with FQs on mortality in HSCT recipients was inconclusive because of small number of trials evaluated. Disclosures: No relevant conflicts of interest to declare.

Description: Abstract 2969 Purpose: Although stringent complete response (sCR) defined by paraprotein negativity on immunofixation and serum free light chain (sFLC) ratio normalization are considered deeper responses in the IMWG criteria, recent report indicated that Multiparameter flow cytometry (MFC)-dased immunophenotypic response (IR) is a more relevant prognostic factor in MM patients. However, data on the prognostic impact of IR and sFLC ratio (sFLCκ/λ) normalization are still scarce. We investigated the prognostic impact of IR and sFLCκ/λ normalization in MM patients treated with novel agents. Patients and Methods: A total of 124 consecutive patients (M:F=68:56; median age, 71 yr) were treated by chemotherapy regimens containing at least one novel agent (thalidomide, bortezomib, lenalidomide)from April 2005 to May 2012. Treatment responses were assessed using the IMWG criteria, and the best response to treatment during the clinical course was assessed by simultaneous serum immunofixation, sFLC measurements, and MFC analysis of bone marrow (BM) plasma cells. Normalization of sFLCκ/λ was defined 2 consecutive normal sFLCκ/λ apart from at least 4 weeks. MFC-defined minimal residual disease (MRD) was evaluated by single-tube 6-color MFC, CD45-CD38 gating strategy, and combination CD19, CD56, and cytoplasmic κ-λ analysis. Clonal plasma cell (PC) negativity by MFC (MFC-negative) was defined as

Description: Background: Myelodysplastic syndrome (MDS) and aplastic anemia (AA) comprise a heterogeneous group of bone marrow failure disorders. As both show profound hypocellular marrow with minimal morphological atypia, differentiation of MDS and AA is often difficult by bone marrow and laboratory examination alone. Red to yellow marrow conversion occurs with age in the appendicular skeleton (AS), where red marrow is converted to yellow marrow until the early 20s. Although an abnormal distribution of red marrow in AS has previously been reported in small numbers of patients with MDS, along with leukemia and lymphoma by MRI, there have been no further reports to date. Here, we examined the distribution of red marrow in AS by low-dose multi-detector CT (MDCT) in AA and MDS. We analyzed the relationships between the abnormal medullary pattern in AS and laboratory variables, subsequent development of leukemic transformation, and survival in MDS patients. Patients: We performed low-dose MDCT of the humerus and femur in 103 untreated adult patients with AA (n = 32) and MDS (n = 71). We retrospectively reviewed the medical records of patients with AA and MDS diagnosed in the Department of Hematology/Oncology at Kameda Medical Center, Kamogawa, Japan, from July 2008 to June 2014. A retrospective review of clinical and laboratory features, including complete blood count, % bone marrow blasts, chromosomal analysis, and International Prognostic Scoring System (IPSS), was performed. WHO classification of MDS patients was as follows: RA (n = 22), RARS (n = 2), RCMD (n = 17), RAEB 1 (n = 18), RAEB 2 (n = 11), and MDS unclassified (n = 1). Overall survival (OS) and leukemia-free survival (LFS) were analyzed in 71 MDS patients by the Kaplan–Meier method and differences between curves were calculated by two-sided log-rank test. CT image acquisition and image analysis: Non-enhanced CT examinations were performed from the base of the skull down to the knee joint with an MS-CT scanner (AQUILION 64; Toshiba, Tokyo, Japan). The bony canals of the humeral and femoral bones were visualized by coronal and sagittal axis image reconstruction. The effective radiation dose associated with whole-body MD-CT was 10.1 mSv (ICRP 26). The dose was comparable to whole-body CT (2.4 mSv). Medullary CT density of the humerus and femur were measured and the results are expressed in Hounsfield units (HU). As the normal adult bone marrow was composed of rich adipocytes and called yellow marrow, it is represented by a low-density CT value between –30 and –100 HU. A value above –30 HU observed in long bony canals was considered to indicate a high-density lesion. The medullary pattern of the appendicular skeleton was categorized as follows: (1) fatty, showing a low signal density marrow; (2) focal, showing abnormally focal high-density lesions; (3) diffuse, showing uniformly high-density marrow. Results: All 15 patients with AA showed a fatty (n = 12, 37.5%) or focal (n = 20, 62.5%) pattern in medullary AS on MDCT, and none showed a diffuse pattern. Among the 71 patients with MDS, 22 (30.9%) had a fatty pattern, 32 (45.1%) had a focal pattern, and 17 (23.9%) had a diffuse pattern. Seventeen patients with diffuse infiltration pattern on MDCT had significantly shorter LFS (P 

Description: For patients with malignant hematological diseases that relapse after allogeneic hematopoietic stem cell transplantation (HSCT), a second HSCT is thought to be a curative option. A second donor is usually searched for due to HLA discrepancy between the graft and the host. However, it is unclear whether HLA discrepancy between the graft and the first donor has an impact on the outcome of second HSCT. To address this issue, we focused on second HSCT patients who had received first HSCT from an HLA-mismatched (MM) donor and compared the effects of HLA discrepancy between graft and first donor with those between graft and host. We retrospectively analyzed 646 patients receiving second HSCT between 1994 and 2016 after an initial HLA-MM transplantation. With regard to the graft versus host results, the one-allele mismatch (1 MM) group (relative risk [RR], 1.88; 95% confidence interval [CI], 0.79-4.45; p=0.163) and more than one-allele mismatch group (≥ 2 MM) (RR, 1.84; 95% CI, 0.75-4.51; p=0.182) had higher risks of grade III-IV acute GVHD compared to the HLA-matched (0 MM) group, although the results were not significant. In contrast, almost no difference in risk of acute GVHD was found among the 0, 1, and ≥ 2 MM group with respect to graft vs. first donor. Furthermore, with regard to graft vs. host, the ≥ 2 MM group showed a significantly higher risk of treatment-related mortality (TRM) (RR, 1.90; 95% CI, 1.04-3.50; p=0.038) compared to the 0 MM group. In contrast, the risk of relapse was slightly lower in the ≥ 2 MM group (RR, 068; 95% CI, 0.44-1.06; p=0.086). Consequently, no significant difference in OS was found among the three groups. In the analysis of each HLA allele MM, B allele MM between graft and host was associated with an increased risk of grade III-IV acute GVHD (RR 2.87; 95% CI, 1.42-5.79; p=0.003) and DR allele MM between graft and host was associated with a lower risk of relapse (RR, 0.75; 95% CI, 0.58-0.95; p=0.018) and higher risk of TRM (RR, 1.44; 95% CI, 1.03-2.00; p=0.033). In contrast, with regard to graft vs. first donor, there were no significant differences in relapse, TRM, or OS among the three groups, and also analysis of each HLA allele MM indicated no associations with relapse, TRM, or OS. These findings suggested that HLA discrepancy between graft and host, rather than between graft and first donor may induce transplant-related immunological responses in second HSCT leading to an increase in TRM. In conclusion, HLA-MM donor is an option after initial HLA-MM transplantation, however, TRM remains a challenge, particularly with a ≥ 2 MM donor regarding to graft versus host. In this study, the biological effects of HLA discrepancy between the graft and the first donor on the outcome appeared negligible, and our findings shed light on the role of nonhematopoietic APCs on transplant-related immunological responses. Figure. Figure. Disclosures Nakamae: Otsuka Pharmaceutical Co., Ltd.: Consultancy, Honoraria, Research Funding. Ichinohe:Mundipharma: Honoraria; Eisai Co.: Research Funding; Ono Pharmaceutical Co.: Research Funding; Alexion Pharmaceuticals: Honoraria; Zenyaku Kogyo Co.: Research Funding; Kyowa Hakko Kirin Co.: Research Funding; CSL Behring: Research Funding; Novartis.: Honoraria; Takeda Pharmaceutical Co.: Research Funding; Taiho Pharmaceutical Co.: Research Funding; Chugai Pharmaceutical Co.: Research Funding; Astellas Pharma: Research Funding; Repertoire Genesis Inc.: Research Funding; Sumitomo Dainippon Pharma Co.: Research Funding; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; JCR Pharmaceuticals: Honoraria; Janssen Pharmaceutical K.K.: Honoraria; Pfizer: Research Funding; Nippon Shinyaku Co.: Research Funding; MSD: Research Funding; Otsuka Pharmaceutical Co.: Research Funding. Kanda:Ono: Consultancy, Honoraria, Research Funding; Shionogi: Consultancy, Honoraria, Research Funding; Nippon-Shinyaku: Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Kyowa-Hakko Kirin: Consultancy, Honoraria, Research Funding; Taiho: Research Funding; Pfizer: Research Funding; Taisho-Toyama: Research Funding; MSD: Research Funding; Novartis: Research Funding; Tanabe-Mitsubishi: Research Funding; Chugai: Consultancy, Honoraria, Research Funding; Otsuka: Research Funding; Dainippon-Sumitomo: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria; Eisai: Consultancy, Honoraria, Research Funding; Sanofi: Research Funding; CSL Behring: Research Funding; Asahi-Kasei: Research Funding; Celgene: Consultancy, Honoraria; Mochida: Consultancy, Honoraria; Alexion: Consultancy, Honoraria; Takara-bio: Consultancy, Honoraria.

Description: Abstract 4051 BACKGROUND: Imaging is playing an increasing role in the diagnosis, staging and treatment response monitoring of patients with multiple myeloma (MM) because of limitation of hematological parameters and uneven distribution of MM lesions in the bone marrow. Although MRI and 18F-FDG-PET/CT have been utilized for visualization of medullary and extra-medullary lesions in patients with MM, both are too time-consuming and expensive for routine clinical use. Whole body Low-dose multidetector CT (WBLD MD-CT) can provide information on the degree of myeloma cell infiltration, especially in the appendicular skeleton. This study was performed to determine the incidence and prognostic implications of abnormal medullary lesions in the appendicular skeleton detected by WBLD MD-CT in patients with monoclonal gammopathy of undetermined significance (MGUS), and asymptomatic and symptomatic MM. We also compared the various hematological parameters with the development of these abnormalities. PATIENTS AND METHODS: Between January 2008 and July 2012, WBLD MD-CT was performed in 89 patients with MM and MGUS as an initial evaluation of lytic bone lesion and medullary and extra-medullary MM lesions. CT image acquisition and analysis were as follows. WBLD MD-CT was performed in an non-enhanced manner on a 16—Salmon staging system (DS), and were 11, 26 and 37 in International Staging System (ISS), respectively. Medullary abnormalities were found in 61 of 73 patients (83.6%). Patients with symptomatic MM had significantly higher mean HU than patients with MGUS/asymptomatic MM (−5.64 vs. −69.99, p 〈 0.001, Fig. 1). In the symptomatic MM, laboratory variables such as albumin, hemoglobin, creatinine, beta-2-microglobulin and presence of poor cytogenetic abnormalities (del17p, IGH-FGFR3, or IGH/MAF on FISH) were not correlated with the mean HU values. Positive correlations between the mean HU value and the amount of intact immunoglobulin (Ig) with IgG and IgA subtypes were observed (correlation coefficient: 0.330 and 0.694, p = 0.049 and 0.005, respectively), but it was not observed in patients with light chain only MM (correlation coefficient: 0.133, p = 0.598). Patients with DS stage 3 showed significantly high HU values compared to those with DS stage 1 and 2 (−35.30 vs. 1.11, p 〈 0.001, Fig. 2) whereas the mean HU value was not significantly different between ISS 3 and 1 or 2 (p = 0.186). Patients with abnormal medullary lesions occupying 〉25% of boney canals had significantly poorer progression-free survival compared to those with 〈 25% (12.5 vs. 15.1 months, p = 0.011, Fig. 3). Moreover, patients with mean HU value 〉0 had significantly shorter median overall survival (40.6 months vs. not reached, p = 0.040, Fig. 4) and tended to have shorter progression-free survival (9.8 vs. 15.7 months, p = 0.106, Fig. 5) compared to those with mean HU value

Description: Abstract 2817 Background: Myelodysplastic syndrome (MDS) and aplastic anemia (AA) are the heterogeneous group of bone marrow failure disorders. AS both shows profound hypocellular marrow without minimal morphologic atypia, differentiation of MDS and AA is often difficult by bone marrow and laboratory examination alone. Red to yellow marrow conversion is occurs with age in the appendicular skeleton (AS), where red marrow is converted to yellow marrow until the age of early 20s. Although abnormal distribution of red marrow in appendicular skeleton has previously reported in small series of patients with MDS, leukemia and lymphoma by MRI, no further study has published so far. Here, we examined distribution of red marrow in AS by low-dose multi-detector CT (MDCT) in AA and MDS. We analyzed the relationship between the abnormal medullary pattern in AS with laboratory variables, subsequent development of leukemic transformation and survivals MDS patients. Patients: We performed a low-dose MDCT of humerus and femurs in 64 untreated adult patients with AA (N=15) and MDS (N=49). Retrospective review of clinical and laboratory features including complete blood count, % of bone marrow blast, chromosomal analysis, and International Prognostic Scoring System (IPSS) was performed. WHO classification of MDS patients was as follows: RA (N=17), RARS (N=2), RCMD (N=9), RAEB (N=19) and MDS unclassified (N=2). Overall survival (OS) and leukemia-free survival (LFS) were analyzed in 49 MDS patients by the Kaplan-Meier and differences between curves were calculated by two-sided log-rank test. Multivariate analysis was Used to assess the effects of prognostic factors - hemoglobin, platelet, bone marrow blast, cytogenetic abnormalities, IPSS score, WHO classification, and MDCT patterns. CT image acquisition and Image analysis: Non-enhanced CT examinations were performed from the base of skull down to the knee joint by MS-CT scanner (AQUILION 64, Tohshiba, Tokyo, Japan). Bony canal of humeral and femoral bone were visualized by coronal and sagittal axis image reconstruction. The effective radiation dose associated with whole body MD-CT was 10.1 mSv. (ICRP 26). The dose was comparable to whole body CT (2.4 mSv.). Medullary CT density of humerus and femurs were measured and the results were expressed as Hounsfield unit (HU). As the normal adult bone marrow was composed of rich adipocytes and called yellow marrow, it is represented by low density CT value between −30 to −100 HU. The value above −30 HU observed in long bony canals was considered as high density lesions. Medullary pattern of appendicular skeletons were categorized as follows: (1) fatty; showing a low signal density marrow (2) focal; showing abnormally focal high density lesions: (3) diffuse; showing uniformly high density marrow. Results: All 15 patients with AA showed a fatty (N=10, 66%) or focal (N=5, 33%) pattern in medullary AS on MDCT and none of them showed diffuse pattern. Conversion from fatty to focal marrow was observed in 9 of 15 AA patients after successful immunosuppressive treatment. Among the 49 patients with MDS, 15 (31%) had fatty pattern, 21 (43%) had focal pattern, and 13 (27%) had diffuse pattern. Patients with diffuse infiltration pattern on MDCT had a significantly low hemoglobin concentration (p

Description: Background : Aldehyde dehydrogenase 2 (ALDH2), a mitochondrial enzyme known to degrade acetaldehyde metabolized from ethanol, is also involved in critically important biological processes such as drug metabolism and DNA repair in hematopoietic stem cells. Based on its role in these biological processes, we hypothesized that a functional ALDH2Glu504Lys polymorphism, which is highly prevalent in East Asian populations, could affect the outcome of hematopoietic transplant recipients. Here, we investigated the association between recipient and donor ALDH2 polymorphism and the clinical outcomes of bone marrow transplantation (BMT). Methods. : We analyzed the Japanese national registry data for 409 patients who underwent allogeneic BMT from an HLA-matched unrelated donor through the Japan Marrow Donor Program. The probability of overall survival (OS) was estimated according to the Kaplan-Meier method. The probabilities of relapse, transplant-related mortality (TRM), engraftment, and graft-versus-host disease (GVHD) were estimated based on cumulative incidence curves. Competing events were death without relapse for relapse, relapse for TRM, death without engraftment for engraftment, and death without GVHD for GVHD. To evaluate the impact of recipient and donor ALDH2 polymorphism on transplant outcomes, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for potential confounders. The Cox proportional hazards model was used to evaluate the effect on OS, whereas Fine and Gray's proportional hazards model was used for the other endpoints. Results.: The median follow-up period in survivors was 6.3 years (range, 0.3-13.1 years). The unadjusted 3-year OS rate was 51% (95% CI, 43%-57%) in Glu/Glu genotype recipients, 52% (43%-60%) in Glu/Lys genotype recipients, and 43% (25%-60%) in Lys/Lys genotype recipients. We did not observe a statistically significant association between the recipient ALDH2 polymorphism and OS. The cumulative incidence of unadjusted 3-year TRM was 28% (21%-34%) in Glu/Glu genotype recipients, 25% (18%-33%) in Glu/Lys genotype recipients, and 50% (29%-68%) in Lys/Lys genotype recipients. The recipient ALDH2 Lys/Lys genotype was significantly associated with a higher TRM, with a HR relative to Glu/Glu genotype of 2.45 (95% CI = 1.22-4.90, P = 0.01). Among the causes of TRM, the incidence rate of organ failure in recipients with the Lys/Lys genotype was twice as high as in recipients with the Glu/Glu genotype (5.9 vs. 3.0 per 1,000 person-days). A statistically significant association between the recipient ALDH2 polymorphism and relapse or GVHD was not observed. With regard to engraftment, the cumulative incidence of platelet engraftment at day 50 was 82% (76%-87%) in Glu/Glu genotype recipients, 80% (72%-85%) in Glu/Lys genotype recipients, and 65% (47%-78%) in Lys/Lys genotype recipients. Compared to the recipient Glu/Glu genotype, the recipient Lys/Lys genotype was marginally significantly associated with delayed platelet engraftment (HR = 0.60, 95% CI = 0.43-1.03, P = 0.06). In contrast, donor ALDH2 polymorphism did not show any significant association with transplant outcomes. Conclusions: We observed poor TRM and delayed platelet engraftment in HLA-matched unrelated BMT recipients with ALDH2 Lys/Lys genotype. Taken functional significance of this polymorphism, our results might indicate that recipient ALDH2 polymorphism could affect the metabolism of chemotherapeutic agents leading to higher TRM and delayed platelet engraftment. Disclosures No relevant conflicts of interest to declare.

Description: We hypothesized that the associations between coffee intake and colorectal cancer (CRC) incidence might differ by immune cell densities in CRC tissue. Utilizing the Nurses’ Health Study and the Health Professionals Follow-up Study, we examined the association of coffee intake with incidence of CRC classified by intraepithelial or stromal T-cell subset densities by multiplex immunofluorescence assay for CD3, CD4, CD8, CD45RO (PTPRC), and FOXP3. We applied inverse probability weighted Cox proportional hazards regression model to control for selection bias and potential confounders. During follow-up of 133,924 participants (3,585,019 person-years), we documented 3,161 incident CRC cases, including 908 CRC cases with available data on T-cell densities in tumor tissue. The association between coffee intake and CRC was not statistically significantly different by intraepithelial or stroma T-cell subset (Pheterogeneity 〉 .38). Hence, there is no sufficient evidence for differential effect of coffee intake on incidence of CRC subtypes classified by T-cell infiltrates.

Description: Background Colorectal cancer (CRC) is a heterogeneous disease that can develop via three major pathways, including the conventional, serrated, and alternate pathways. We aimed to examine whether the risk factor profiles differ according to pathway-related molecular subtypes. Methods We examined the association of 24 risk factors with four CRC molecular subtypes based on a combinatorial status of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), BRAF and KRAS mutations by collecting data from two large US cohorts. We used inverse probability weighted duplication-method Cox proportional hazards regression to evaluate differential associations across subtypes. Results We documented 1,175 CRC cases with molecular subtype data: subtype 1 (n = 498; conventional pathway; non-MSI-high, CIMP-low/negative, BRAF-wildtype, KRAS-wildtype), subtype 2 (n = 138; serrated pathway; any MSI status, CIMP-high, BRAF-mutated, KRAS-wildtype), subtype 3 (n = 367; alternate pathway; non-MSI-high, CIMP-low/negative, BRAF-wildtype, KRAS-mutated), and subtype 4 (n = 172; other marker combinations). Statistically significant heterogeneity in associations with CRC subtypes was found for age, sex, and smoking, with a higher hazard ratio (HR) observed for the subtype 2 (HR per 10 years of age = 2.64, 95% CI = 2.13-3.26; HR for female = 2.65, 95% CI = 1.60-4.39; HR per 20-pack-year of smoking = 1.29, 95% CI = 1.14-1.45) than other CRC subtypes (All P for heterogeneity 〈 0.005). A stronger association was found for adiposity measures with subtype 1 CRC in men and subtype 3 CRC in women, and for several dietary factors with subtype 1 CRC, although these differences did not achieve statistical significance at α = 0.005 level. Conclusions Risk factor profiles may differ for CRC arising from different molecular pathways.